Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while IDEXX Laboratories, Inc. trades at $565 (market cap $44.46B). The key difference: Alnylam Pharmaceuticals, Inc. and IDEXX Laboratories, Inc. are close in size by market cap. Which is the better fit depends on your goals.
| ALNY | IDXX | |
|---|---|---|
Market Cap | $39.89B | $44.46B |
Sector | Health | Health |
52-Week High | $491.22 | $766.68 |
52-Week Low | $278.09 | $514.61 |
Enterprise Value | $38.15B | $45.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IDXX trades at $563.57, up 0.89% today, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.47 surpassing estimates. Revenue grew to $4.3B in 2025, with a robust net income margin of 24.63%. Analyst consensus is bullish with a $645 price target. Recent news highlights innovation in veterinary diagnostics and AI integration.
The outlook remains positive driven by earnings growth and market leadership, though high valuation multiples pose a risk. Key catalysts include upcoming Q2 2026 results and continued demand in pet healthcare. Risks involve competitive pressures and macroeconomic sensitivity. The stock offers growth potential but requires monitoring of valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
